Dermatology Times has published new guidance on one of the most routine yet most contested decisions in acne care: when to reach for an oral antibiotic, and when an oral retinoid is the better systemic choice.

The article, titled "How to Choose Oral Antibiotics and Retinoids for Acne Management," addresses a question that practicing dermatologists face daily. Systemic therapy is a mainstay for moderate-to-severe inflammatory acne, but the two dominant drug classes carry very different risk-benefit profiles, and selection criteria continue to shift as stewardship concerns reshape prescribing habits.

Why does antibiotic selection remain contentious?

Antibiotic resistance has become a central constraint on acne management. Guidelines and specialty bodies have increasingly urged clinicians to limit the duration of oral antibiotic courses, to avoid using antibiotics as monotherapy, and to pair them with topical agents such as retinoids or benzoyl peroxide that reduce resistance pressure.

The Dermatology Times piece sits squarely in that conversation. It examines how prescribers can align drug selection with current expectations around responsible antibiotic use, without compromising clearance outcomes for patients with inflammatory disease.

Where do oral retinoids fit?

Oral retinoids occupy a distinct niche in the systemic armamentarium, reserved for severe, refractory, or nodulocystic disease where antibiotics are unlikely to deliver durable control. The trade-off is well known to clinicians: high efficacy against nodulocystic and scarring presentations, offset by a demanding monitoring and risk-management profile.

The article's framing — choosing between the two classes rather than defaulting to one — reflects how the field has moved away from reflexive, prolonged antibiotic courses toward a more deliberate sequencing of therapy, with retinoids positioned as both a bridge off antibiotics and a definitive option for the severest phenotypes.

What does the piece offer practicing clinicians?

The article is written for the prescribing dermatologist rather than the researcher. Its value lies in consolidating selection logic that is usually scattered across guidelines, label information, and institutional stewardship policies into a single practical walkthrough.

Key themes the piece engages include:

• Matching the systemic agent to acne severity and phenotype
• The role of combination therapy in limiting antibiotic exposure
• Transitioning patients from antibiotics to retinoid-based maintenance
• Practical constraints that shape real-world prescribing decisions

The bigger picture

The article lands at a moment when acne therapeutics are expanding on the topical side, with newer fixed-dose combinations and androgen-based options reducing reliance on systemic antibiotics for some patients. That makes selection criteria for the remaining systemic prescriptions more, not less, important — every oral course now invites justification.

For clinicians, the practical takeaway is that antibiotic and retinoid selection is no longer a binary severity call but a sequencing decision embedded in a longer treatment plan. How quickly stewardship norms and newer topical agents further reduce oral antibiotic use in acne will be one of the defining prescribing trends dermatology watches over the coming years.